Andreoli MT, Pinnolis M, Kieser T, Sun J, Andreoli CM. Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration. Digit J Ophthalmol [Internet]. 2015 Sep. 11 [cited 2026 May 2];21(3):29-34. Available from: https://djo.harvard.edu/index.php/djo/article/view/380